ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08808
0,06%
Bitcoin
67.020,74
1,30%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. Kanada
  5. TSXV
  6. Revive Therapeutics Ltd (RVV)

  7. Revive Therapeutics Ltd (RVV) News

RVV

Revive Therapeutics (RVV)

Revive Therapeutics Ltd
Von:
Sortieren nach:
 Showing the most relevant articles for your search:TSXV:RVV
DatumZeitQuelleÜberschriftSymbolFirma
29/03/202215h57InvestorsHub NewsWireRevive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19TSXV:RVVRevive Therapeutics Ltd
24/02/202214h35InvestorsHub NewsWireHAVN Life Secures Purchase Order for Controlled Substance Sale to Revive Therapeutics Ltd. for Use in Clinical ResearchTSXV:RVVRevive Therapeutics Ltd
16/02/202214h03InvestorsHub NewsWireRevive Therapeutics Receives FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver TransplantationTSXV:RVVRevive Therapeutics Ltd
19/01/202214h19InvestorsHub NewsWireRevive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19TSXV:RVVRevive Therapeutics Ltd
07/01/202214h05InvestorsHub NewsWireRevive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19TSXV:RVVRevive Therapeutics Ltd
16/11/202114h00InvestorsHub NewsWireRevive Therapeutics Announces Published Research Results on Bucillamine as Potential Inhibitor of SARS-CoV-2 Infection Delta VariantTSXV:RVVRevive Therapeutics Ltd
22/09/202113h30InvestorsHub NewsWireRevive Therapeutics Included in AdvisorShares® Newly Launched Psychedelics ETFTSXV:RVVRevive Therapeutics Ltd
21/09/202117h50AllPennyStocks.comETF Inclusion Sends Psychedelic Stock SoaringTSXV:RVVRevive Therapeutics Ltd
15/07/202120h47InvestorsHub NewsWireRevive Therapeutics Provides Update on FDA Phase 3 Clinical Trialfor Bucillamine in COVID-19TSXV:RVVRevive Therapeutics Ltd
17/06/202114h59InvestorsHub NewsWireRevive Collaborates With University of Health Sciences Antigua To Pioneer Clinical Research of PsychedelicsTSXV:RVVRevive Therapeutics Ltd
08/06/202115h12InvestorsHub NewsWireRevive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in IndiaTSXV:RVVRevive Therapeutics Ltd
17/05/202115h48InvestorsHub NewsWireRevive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop Oral Psilocybin Thin Film StripTSXV:RVVRevive Therapeutics Ltd
27/04/202115h51InvestorsHub NewsWireRevive Therapeutics Files For FDA Orphan Drug Designation for Psilocybin in Traumatic Brain InjuryTSXV:RVVRevive Therapeutics Ltd
22/04/202114h26InvestorsHub NewsWireRevive Therapeutics Announces Successful Research Results for Oral Thin Film Psilocybin and Filing of U.S. Provisional ....contTSXV:RVVRevive Therapeutics Ltd
19/03/202112h56InvestorsHub NewsWireRevive Therapeutics Announces Successful Research Results for Psilocybin to Treat Traumatic Brain Injury and Filing of ...ContTSXV:RVVRevive Therapeutics Ltd
17/02/202115h53InvestorsHub NewsWireRevive Therapeutics Acquires Unique Psilocybin AssetsTSXV:RVVRevive Therapeutics Ltd
18/01/202115h51InvestorsHub NewsWireHow Combat Sports Are Researching Micro-Dosing Psychedelics To Treat Brain InjuriesTSXV:RVVRevive Therapeutics Ltd
14/01/202114h30InvestorsHub NewsWireRevive Therapeutics Announces Research Collaboration with North Carolina State UniversityTSXV:RVVRevive Therapeutics Ltd
31/12/202014h30InvestorsHub NewsWireDr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 StudyTSXV:RVVRevive Therapeutics Ltd
23/12/202015h57InvestorsHub NewsWireRevive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for BucillamineTSXV:RVVRevive Therapeutics Ltd
12/11/202015h00InvestorsHub NewsWireRevive Therapeutics Provides Update on Oral Thin Film Product with PsilocybinTSXV:RVVRevive Therapeutics Ltd
20/10/202016h58InvestorsHub NewsWireRevive Therapeutics Signs Supply Agreement With Havn Life Sciences for Psychedelic CompoundsTSXV:RVVRevive Therapeutics Ltd
29/09/202015h39InvestorsHub NewsWireRevive Therapeutics Announces Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19TSXV:RVVRevive Therapeutics Ltd
21/09/202016h15InvestorsHub NewsWireRevive Therapeutics Provides Corporate Update on its Psychedelics Therapeutics ProgramsTSXV:RVVRevive Therapeutics Ltd
16/09/202015h59InvestorsHub NewsWireRevive Therapeutics Announces IRB Approval of US Expanded Access Treatment Program (Compassionate Use) for Bucillamine in COV...TSXV:RVVRevive Therapeutics Ltd
02/09/202015h24InvestorsHub NewsWireRevive Therapeutics Enters into Clinical Trial Agreement to Evaluate Psilocybin for the Treatment of Methamphetamine UseTSXV:RVVRevive Therapeutics Ltd
05/12/201418h01PR Newswire (Canada)Revive Therapeutics Prices and Files Final Prospectus for Equity FinancingTSXV:RVVRevive Therapeutics Ltd
27/06/201413h00Marketwired CanadaRevive Therapeutics Ltd. Announces Positive Results of REV-001 Phase 2A Proof-Of-Concept StudyTSXV:RVVRevive Therapeutics Ltd
27/06/201413h00MarketwiredRevive Therapeutics Ltd. Announces Positive Results of REV-001 Phase 2A Proof-Of-Concept StudyTSXV:RVVRevive Therapeutics Ltd
05/06/201413h00MarketwiredRevive Therapeutics Ltd. Submits Pre-IND Package to the US FDA for Its Gout Drug Candidate, REV-002TSXV:RVVRevive Therapeutics Ltd
 Showing the most relevant articles for your search:TSXV:RVV

Kürzlich von Ihnen besucht

TSX
5254
Arent
AMEX
IYZ
iShares US Telecommunica...
BIT
UITA7S
Unicredit Bank
TG
2BN
Barnes & Noble Education
NASDAQ
FNXJIX
Equity Income Opportunit...
USOTC
CNNB
Cincinnati Bancorp (QX)
BOV
GGBRE157
GGBRE157 Ex:12,79
EU
XS1953146245
ING Groep NV 3.000% unti...
DGFX
HXAUSDT
HXAcoin
BIT
UC0ZZR
Unicredit Bank
USOTC
JPSTF
Japan Post BK (PK)
TG
GKS
GK Software
AMEX
RPHS
Regents Park Hedged Mark...
BIT
P130I3
BNP PARIBAS ISSUANCE
COIN
GFNCASHGBP
AMEX
WBIF
WBI BullBear Value 3000 ...
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten